Department of Otorhinolaryngology-Head and Neck Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
Department of Otorhinolaryngology, Kanazawa Medical University, Kahoku, Japan.
Auris Nasus Larynx. 2024 Feb;51(1):99-105. doi: 10.1016/j.anl.2023.04.010. Epub 2023 Apr 27.
To determine if tokishakuyakusan (TSS) is effective for treating post-infectious olfactory dysfunction (PIOD) compared with vitamin B (mecobalamin).
We conducted a randomized, nonblinded clinical trial. Patients with PIOD enrolled in 17 hospitals and clinics from 2016 to 2020 were randomly divided into two groups, and we administered TSS or mecobalamin for 24 weeks. Their olfactory function was examined using interviews and T&T olfactometry. The improvement of olfactory dysfunction was assessed following the criteria of the Japanese Rhinologic Society.
Overall, 82 patients with PIOD were enrolled in this study. In the TSS and mecobalamin groups, 39 patients completed the medication regimen. In the TSS and mecobalamin groups, olfactory dysfunction was significantly improved based on self-reports and olfactory test results. The improvement rate of olfactory dysfunction was 56% in the TSS group and 59% in the mecobalamin group. Early intervention within 3 months produced a better prognosis than the treatment initiated after 4 months. Furthermore, age and sex differences were not observed. Both medications produced no severe adverse events.
The present study showed that TSS and mecobalamin might be useful for treating PIOD.
与维生素 B(甲钴胺)相比,确定六合氨基酸(TSS)治疗感染后嗅觉障碍(PIOD)是否有效。
我们进行了一项随机、非盲临床试验。2016 年至 2020 年期间,17 家医院和诊所共招募了 82 名 PIOD 患者,他们被随机分为两组,分别接受 TSS 或甲钴胺治疗 24 周。使用访谈和 T&T 嗅觉计检查他们的嗅觉功能。根据日本鼻科学会的标准评估嗅觉障碍改善情况。
共有 82 名 PIOD 患者参与了这项研究。在 TSS 和甲钴胺组中,39 名患者完成了药物治疗。在 TSS 和甲钴胺组中,嗅觉障碍在自我报告和嗅觉测试结果方面均有显著改善。TSS 组嗅觉障碍的改善率为 56%,甲钴胺组为 59%。3 个月内的早期干预比 4 个月后的治疗效果更好。此外,未观察到年龄和性别差异。两种药物均未产生严重的不良反应。
本研究表明,TSS 和甲钴胺可能对治疗 PIOD 有效。